# A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma

> **NCT05420324** · PHASE2 · COMPLETED · sponsor: **Eucure (Beijing) Biopharma Co., Ltd** · enrollment: 20 (actual)

## Conditions studied

- Mucosal Melanoma

## Interventions

- **DRUG:** YH003
- **DRUG:** Pembrolizumab
- **DRUG:** albumin paclitaxel

## Key facts

- **NCT ID:** NCT05420324
- **Lead sponsor:** Eucure (Beijing) Biopharma Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-13
- **Primary completion:** 2024-03-04
- **Final completion:** 2024-03-04
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05420324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05420324, "A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05420324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*